Form 4: ANAB CFO Mulroy Exercises, Sells 10,000 Shares

AnaptysBio's Chief Financial Officer, Dennis Mulroy, exercised stock options and subsequently sold 10,000 shares of common stock for a significant gain.

Summary

• Dennis Mulroy, Chief Financial Officer of AnaptysBio, Inc. (ANAB), executed a transaction on December 22, 2025.
• Mulroy acquired 10,000 shares of common stock by exercising employee stock options at a price of $20.16 per share.
• Immediately following the option exercise, Mulroy sold all 10,000 of these shares at a price of $50.00 per share.
• This transaction was conducted in accordance with a Rule 10b5-1 trading plan that was adopted by Mulroy on April 11, 2025.
• After these transactions, Mulroy's direct beneficial ownership of common stock stands at 9,401 shares.
• Mulroy also retains 60,600 fully vested employee stock options and an additional 339,440 unvested options, totaling 400,040 derivative securities.

Sentiment

Score: 6

Explanation: The transaction is a routine insider sale under a 10b5-1 plan, which is generally neutral. The significant profit realized by the CFO is a positive for the individual, but the sale itself could be viewed with slight caution by some investors, though mitigated by the pre-planned nature.

Positives

• The Chief Financial Officer realized a substantial profit from the sale of shares, with a sale price of $50.00 per share against an exercise price of $20.16 per share.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent sale not based on immediate, non-public information.

Negatives

• The sale of shares by a key executive, even if pre-planned, could be interpreted by some investors as a signal of reduced confidence, although the Rule 10b5-1 plan mitigates this concern.

Future Outlook

NA

Management Comments

• The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 11, 2025.
• The stock option is fully vested.
• In addition to the remaining options to purchase 60,600 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 339,440 shares of common stock, which options vest according to their terms.

Industry Context

This is an insider transaction report and does not provide broader industry context or trends. It reflects an individual executive's personal financial planning.

Stakeholder Impact

• Shareholders: The sale by a CFO, even if pre-planned, might lead to minor concerns about insider sentiment, but the overall impact is likely minimal given the routine nature of 10b5-1 plans. The realized profit highlights the value of executive compensation.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction by the CFO, involving the exercise of vested options and subsequent sale of shares. While the CFO realized a substantial gain, the transaction was executed under a Rule 10b5-1 plan, which mitigates concerns about opportunistic selling based on new information. The filing does not provide any new material information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

AnaptysBio, ANAB, Dennis Mulroy, CFO, Insider Trading, Stock Option Exercise, Share Sale, Form 4, Rule 10b5-1, Beneficial Ownership